APACC
Meeting category
Date(s)
28 Jun 2018 - 30 Jun 2018
Location
Hong Kong, China
Organizer
Titanium Level Support
Sponsor logos
ViiW
gilead

APACC 2018

Related Enduring Materials

Enduring Materials

 Day 1 - Thursday, 28 June 2018

-
Professor David Cooper Tribute Eulogy
Praphan Phanuphak
Praphan Phanuphak, MD, PhD
Thai Red Cross AIDS Research Centre, Thailand
Presentation
Mark Boyd, BA, BM, BS, DCTH&H, MHID, MD, FRACP
University of Adelaide, Australia
Plenairy session 1: Strategies to end AIDS in the Asia-Pacific -
David Cooper Memorial Lecture: Current effort to control the epidemic in the region
Nittaya Phanuphak, MD, PhD
Institute of HIV Research and Innovation in Bangkok, Thailand
WHO’s regional strategies
Polin Chan
Polin Chan, MD
World Health Organization
Parallel session 1: Future of ART in LMICs -
IP and regulatory barriers to access ART and drugs for co-infections in LMICs
Menghaney
Leena Menghaney
Médecins Sans Frontières (MSF), India
Treatment regimens for the public health approach – do we need to change?
Nicholas Paton, MD, FRCP
National University of Singapore, Singapore
Parallel session 2: Evolving epidemiology -
Derivation of population mixing patterns from virus sequence data and their impacts on the modelling of HIV epidemics in MSM
Ngai Sze Wong
#1
Transmitted drug resistance and impact on long-term clinical outcomes in the VMVN clinical trial in Hanoi, Vietnam
Thuy Le
#2
Treatment outcome and drug resistance mutations among patients on LPVr-containing second-line antiretroviral therapy in Vietnam (Not available)
Junko Tanuma
#3
Chemsex: prevalence, characteristics and associated risk profiles of men who have sex with men in South Australia: a cross-sectional cohort study
Carole Khaw
#4

Day 2 - Friday, 29 June 2018

Planairy session 2: Management of advanced HIV disease -
Current gaps between policy and practice in the Asia Pacific region
Nagalingeswaran Kumarasamy, MD, FRCP, PhD
Voluntary Health Services, Infectious Diseases Medical Centre, India
Challenges in the management of advanced HIV disease from the clinical perspective
Linghua Li, MD, PhD
Guangzhou Eighth People’s Hospital, China
Public health approach to reduce the burden of advanced HIV disease
Polin Chan
Polin Chan, MD
World Health Organization
Parallel session 3: Social media and mHealth -
Social media to increase HIV testing uptake in China
Weiming Tang
Weiming Tang, PhD, MS, MD
Dermatology Hospital of Southern Medical University, China
Systematic review of social media HIV interventions
Bolin
Bolin Cao, PhD
Shenzhen University, China
Social media platforms for LGBT inclusion
Laurindo Garcia
Laurindo Garcia
B-Change Group, the Philippines and Singapore
Parallel session 4: Co-infections and complications -
Human papillomavirus prevalence and behavioral risk factors among HIV-Infected men in central Taiwan
Yuan-Ti Lee
#5
Malignancies in adults living with HIV in Asia (Not available)
Awachana Jiamsakul
#6
Drivers for mental health issues among young and old HIVinfected individuals and opportunities for intervention
Reena Rajasuriar
#7
Asymptomatic talaromyces mareffei infection is associated with HIV mortality (Not yet available)
Thu Nguyen Thi Mai
#8
Outcome of HCV treatment by direct acting antiretroviral (DAAs) among HCV/HIV co-infections in Vietnam
Thu Nguyen
#9
Parallel session 5: Poster discussion on MSM and TG sexual risk in Asia -
Identifying MSM-competent physicians in China: A national online cross-sectional survey among physicians who see male HIV/STD patients
Peipei Zhao
#57
Pre-exposure prophylaxis (PrEP) service in a South East Asian university hospital – one year experience
Dariusz Piotr Olszyna
#66
Treatment for anorectal Chlamydia trachomatis infection with azithromycin 1g single dose in mem who have sex with men w/o HIV infection
Daisuke Mizushima
#69
Reducing condomless sex among Chinese Men Who Have Sex with Men through repeated exposure to online videos: results from an online cohort study
Wenting Huang
#81
The pattern of risk compensation in MSM enrolled in a pilot PrEP project
Tsz Ho Kwan
#82
Voices of the hidden: Implementation of the people living with HIV stigma index in Taiwan
Yi-Chi Chiu
#91
Parallel session 6: Poster discussion on strategies to improve HIV outcomes in Asia -
Cost-effectiveness of Dolutegravir in HIV-1 treatment-naïve patients in China
Yogesh Punekar
#19
DTG versus LPV/r in second line (DAWNING): outcomes by WHO-recommended NRTI backbone
Yinzhong Shen
#34
Assessing the efficacy of Lopinavir /ritonavir based preferred and alternative second-line regimens on HIV-infected patients : a meta-analysis as a key evidence support for WHO recommendations
Yaokai Chen
#35
Routine versus targeted viral load strategy among patients starting ART in Hanoi, Vietnam
Todd Pollack
#51
Replicating the success: Using an HIV model of peer driven intervention (PDI+) to increase TB new case detection in Cambodia
Kolab Chhim
#64
Optimal timing of antiretroviral therapy for HIV-infected patients with cryptococcal meningitis: A systematic review and meta-analysis
Yaokai Chen
#74
Parallel session 7: Optimizing clinical management of long-term complications -
Improving tolerability by optimizing ART
Kiat Ruxrungtham, MD
Chulalongkorn University, Thailand
Addressing long-term complications to improve health outcomes in HIV
Reena Rajasuriar, MPharm, PhD
University of Malaya, Malaysia
Parallel session 8: Prevention and linkage to treatment -
Feasibility and outcome of rapid initiation of antiretroviral treatment among newly-diagnosed HIV-positive patients at a tertiary center in Taiwan
Yi-Chia Huang
#10
Impact of initiation of combination antiretroviral therapy according to the WHO recommendations on the survival of HIV-positive patients in Taiwan
Wang-Da Liu
#11
Renal and liver function changes among post-exposure prophylaxis clients at the Thai Red Cross Anonymous Clinic in Bangkok
Samanan Thongyoi
#12
Changes in creatinine and estimated glomerular filtration rate during the first 12-month period of pre-exposure prophylaxis among PrEP-30 clients at the Thai Red Cross anonymous clinic
Piyanuch Tuntikul
#13
Debate: IPT should be implemented for all HIV patients in the Asia-Pacific -
Pro debater: IPT should be implemented for all HIV patients in the Asia-Pacific
Acceptability and experiences of assisted and unassisted oral fluid testing among men who have sex with men and transgender women in Thailand: Implications to roll out and scale-up
Con debater: IPT should be implemented for all HIV patientsin the Asia-Pacific
Thuy Le, MD, DPhil
Duke University; Oxford University Clinical Research Unit, United States / Vietnam

Day 3 - Saturday, 30 June 2018

Parallel session 9: Panel discussion: Key populations-led health service models -
Why we need KPLHS to end AIDS in the Asia Pacific
Michael Cassell
Michael Cassell, PhD, MEM, MA
FHI 360, Thailand
KPLHS for same-day ART and differentiated service delivery in Thailand
Chamrong Phaengnongyang
Chamrong Phaengnongyang
Service Workers in Group Foundation, Thailand
KPLHS for HIV testing and PrEP in Vietnam
Kimberly Green
Kimberly Green, MA, PhD
PATH, Vietnam
Sustainability of KPLHS through capacity building platform
Rangsima Airawanwa
Rangsima Airawanwat, PhD
Thai Red Cross AIDS Research Centre, Thailand
Parallel session 10: Immune interventions to control HIV -
Introduction to immunology - What clinicians need to know
Paul Cameron
Paul Cameron, BMedSci, MBBS, PhD, FRACP, FRCPA
University of Melbourne, Australia
Broadly neutralizing antibodies for treatment and prevention of HIV-1
Daniel Kuritzkes, MD
Brigham and Women's Hospital / Harvard Medical School, United States
Plenairy session 3: Viral Hepatitis -
What’s new in Hepatitis B treatment & diagnostics
Seng Gee Lim
Seng Gee Lim, MBBS, FRACP, FRCP, MD
National University of Singapore, Singapore
Hep C: How we are going to get to hep C elimination from a clinician’s perspective
Gail Matthews
Gail Matthews, MBCHB, MRCP (UK), FRACP, PhD
The Kirby Institute, UNSW, Australia
Hep C: Country experience with elimination efforts
Vithurneat Hang
Vithurneat Hang, PhD
Medecins Sans Frontieres (MSF), Cambodia
Capacity building sessions -
How to do a systematic review
Matthew Law
Matthew Law, BA (Hons), MSc, PhD
The Kirby Institute, Australia
Joseph Tucker, MD, PhD, AM
UNC Chapel Hill, United States
Research methodology
Mark Boyd, BA, BM, BS, DCTH&H, MHID, MD, FRACP
University of Adelaide, Australia
Matthew Law
Matthew Law, BA (Hons), MSc, PhD
The Kirby Institute, Australia
Getting involved in clinical research: from clinical trials to sub-studies
Nicholas Paton, MD, FRCP
National University of Singapore, Singapore
Thuy Le, MD, DPhil
Duke University; Oxford University Clinical Research Unit, United States / Vietnam
Overview
Welcome

The very successful 3rd Asia Pacific AIDS & Co-infections Conference (APACC) took place from 28 to 30 June 2018 in Hong Kong.

Organizing Committee would like to thank all invited speakers and participants for their contribution to this conference!

We would like to thank our supporters ViiV Healthcare, Gilead Sciences, Mylan, MSD, AbbVie and Hong Kong Toursim Board for making this event possible. 

General Information 

Unique Features
- A program with a special focus on the needs in Asia and the Pacific

- A true scientific platform for regional clinicians and clinical researchers to present their data

- Insights into important clinical developments and updates on ongoing and new trials

- Capacity building workshops and career development sessions for young professionals

- A great opportunity to network with your colleagues throughout Asia
Meeting Objectives
This meeting aims to:

- Promote dissemination and successful translation of new knowledge regarding HIV and co-infections while facilitating a neutral environment

- Foster new and lasting cross-disciplinary partnerships and collaborations between researchers in HIV, hepatitis, tuberculosis, policymakers, and NGOs, among others, in order to improve knowledge sharing, with the end goal of improving healthspan within the rapidly growing HIV/AIDS population

- Attract, showcase, and maintain new, early career, and underrepresented investigators to this multidisciplinary area of research and to translate novel findings into clinical practice
Learning Objectives
After participating in this activity, participants will be able to:

- Describe the major achievements and challenges in antiviral therapy for HIV and/or hepatitis-positive patients in the Asia Pacific region

- Identify improved treatment options for their patients

- Initiate (research) collaborations to further improve the level of knowledge on clinical management in the Asia Pacific region

- Use gained knowledge to make/advocate for appropriate adjustments to policies in public, institutional, and private settings

Practical Information 

Disclaimer
This conference is intended for educational purposes only and aims to offer participants the opportunity to share information. The Organizing Secretariat of this conference, Virology Education, cannot accept any liability for the scientific content of the sessions or for any claims which may result from the use of information or publications from this conference. Virology Education disclaims all liability for injuries or losses of whatever nature incurred by individuals attending the conference.
Liability and Insurance
By registering for the conference participants agree that the organizers do not accept responsibility for medical-, travel- or personal insurance. Participants are advised to take out their own insurance policies.
Photographs, Audio, and Video Recording
Photographs, audio, and video recordings are not permitted at the official conference sessions. Only the official medical writer appointed by the organization may make recordings. All presentations will be posted here as soon as possible after the conference is finished, provided the speaker has given permission to do so.
Support
Support
Contributor Level
Language